EuroAPI (EAPI.PA)

Executive Summary

EuroAPI, a leading small-molecule active pharmaceutical ingredient (API) manufacturer, was spun off from Sanofi in 2022 and holds one of the industry's largest portfolios with approximately 200 APIs. The company combines a legacy API business with a growing contract development and manufacturing organization (CDMO) segment, serving both captive and external customers. Despite a strong product library and manufacturing footprint, EuroAPI faces challenges from generic API pricing pressure and the need to rebalance its customer mix away from its former parent. The company is actively pursuing strategic partnerships, capacity expansions, and portfolio optimization to improve utilization and margins. With a diversified pipeline and investments in high-value molecules, EuroAPI aims to establish itself as a standalone leader in the small-molecule CDMO space. Near-term financial performance will depend on execution of cost-saving initiatives and the ramp-up of commercial-scale manufacturing contracts.

Upcoming Catalysts (preview)

• Q3 2026Q3 2026 Earnings Release – Margin Improvement from Restructuring65% success
• Q4 2026New Long-Term CDMO Contract Win with a Top Pharma Company50% success
• H1 2027Announcement of Capacity Expansion at Key European Site70% success